Our program uses a combination of genetic approaches, particularly gene-targeting technologies, to explore the general hypothesis that proteases, protease receptors, substrates and inhibitors associated with blood coagulation and fibrinolysis are critical determinants of tumor cell metastasis, antimicrobial host defense, cardiovascular disease and inflammatory disease (e.g., inflammatory joint, bowel and CNS disease).
Recent advances have established the contribution of hemostatic proteases and their substrates in vascular- and immune-cell signaling, regulation of endothelial / blood cell function and disease pathobiology. This is a major driving force for our basic and translational research initiatives.
Given that hemostatic factors appear to contribute to multiple disease processes, our initiatives may illuminate novel therapeutic strategies for the prevention or treatment of a wide spectrum of common, life-threatening diseases.
Joseph Palumbo, MD
Eric Mullins, MD